全部

全部
news
project

86-013816172263

National Free Consultation Hotline

CH EN

Products

Home

Adenosine 5'-monophosphate disodium salt

Other Names :

AMP-Na2、Disodium AMP 、AMP disodium、Disodium5'-amp、Adenylicaciddisodiumsalt、 5'-Adenosine Monophosphate Disodium Salt

CAS No. :

4578-31-8

Formula :

C10H12N5Na2O7P

Mol. Mass :

391.18

Specifications :

99% powder

Appearance :

white powder

Applications :

Energy Metabolism
Cardioprotection
Neuroprotection
Anti-fatigue

Package :

5kg/bag, 25kg/drum

Shipment :

By DHL, by air, by sea

Get A Quote

Adenosine 5'-Monophosphate Disodium Salt (AMP-Na₂)

———————————————————————————————————————————————————————————————————————————

1. Product Overview & Key Advantages

Adenosine 5'-monophosphate disodium salt (AMP-Na₂) is a naturally occurring nucleotide that serves as a direct precursor to ATP, playing a pivotal role in energy metabolism, cardiovascular protection, and neurological regulation. Its core advantages include:

• Oral bioavailability (12%, significantly higher than ATP’s <1%)

• Rapid conversion to ATP (via the "salvage pathway" to enhance cellular energy)

• Multi-organ protection (heart, brain, skeletal muscle)

Market Data:

• The global energy metabolism modulator market is projected to reach $9.2 billion by 2030 (CAGR 7.3%).

• AMP-Na₂ adoption in sports nutrition and cardiovascular drugs is growing at 15% annually (Grand View Research, 2023).

2. Chemical Properties & Manufacturing Processes

1. Molecular Characteristics

Parameter	Value
CAS Number	4578-31-8
Molecular Formula	C₁₀H₁₂N₅Na₂O₇P
Solubility	>500 mg/mL in water (pH 7.4)
Stability	<5% annual degradation (25°C, dark)

2. Manufacturing Methods Comparison

Method	Advantages	Disadvantages	Key Manufacturers
Microbial Fermentation	Eco-friendly, low cost	Requires purification (~98% purity)	Kyowa Hakko
Chemical Synthesis	High purity (≥99.5%)	Organic solvent residues	Sigma-Aldrich

• Patented Technologies:

CN112142806A: High-yield E. coli fermentation process.

US2021007102A1: Ion-exchange chromatography purification.

3. Mechanisms of Action & Pharmacodynamics

1. Energy Metabolism Regulation

• ATP Production Pathway: AMP-Na₂ → Adenosine Kinase (ADK) → ADP → ATP (Salvatore et al., 2016).

• Clinical Effect: 250 mg oral dose ↑ muscle ATP by 18% (NCT03829436).

2. Cardiovascular Protection

• Mechanism: Activates endothelial A₂A receptors, ↑ NO release (Zhou et al., 2010).

• Clinical Data:

— Coronary artery disease: 500 mg/day ↑ coronary blood flow by 22%.

— Heart failure: 600 mg/day ↑ LVEF by 6.5% (NCT04572399).

3. Neuroprotection

• Synaptic Plasticity: Upregulates BDNF expression, improves memory in Alzheimer’s models (Chen et al., 2019).

4. Clinical Applications & Dosage

1. Cardiovascular Diseases

Indication	Recommended Dose	Efficacy Endpoints
Chronic Heart Failure	600 mg/day	LVEF↑6.5%, NT-proBNP↓20%
Myocardial Ischemia	500 mg/day	↓35% angina frequency

2. Sports Medicine

• Anti-Fatigue: Athletes taking 500 mg/day extended time-to-exhaustion by 15% (Zhang et al., 2021).

5. Competitive Product Analysis

1. AMP-Na₂ vs. ATP

Parameter	AMP-Na₂	ATP
Administration	Oral/IV	IV only
Half-life	4–6 hours	2–3 minutes
Cost	$800/kg	$5,000/kg
Key Advantage	Long-term oral therapy	Acute medical use only

2. AMP-Na₂ vs. Coenzyme Q10 (CoQ10)

• Target:

AMP-Na₂: Direct ATP precursor.

CoQ10: Mitochondrial electron transport chain.

• Clinical Outcome:

AMP-Na₂ more effective for exercise endurance (↑15% vs. CoQ10↑8%).

3. AMP-Na₂ vs. Creatine

Parameter	AMP-Na₂	Creatine
Onset of Action	Rapid (30 minutes)	Requires loading (5–7 days)
Target Users	Cardiovascular patients + athletes	Strength athletes

6. Formulation Innovations & Stability

1. Leading Formulations

Formulation	Advantage	Example Product
Enteric-coated Tablet	Gastric acid resistance	AMP-Cardio®
Sublingual Film	Fast absorption (Tmax 15 min)	AMP-SL™
Injectable Solution	Acute myocardial ischemia	AMP-IV®

2. Stability Advances

• Microencapsulation: Eudragit® coating extends shelf life to 36 months.

• Lyophilized Powder: Stable >3 years at 4°C (PharmaTech, 2023).

7. Safety & Market Outlook

1. Safety Profile

• LD₅₀: >5,000 mg/kg in rats (OECD 423).

• Adverse Effects: Mild GI discomfort at >1,000 mg/day.

2. Regulatory Status

Region	Regulatory Status	Max Daily Dose
USA	FDA GRAS (No. 1022)	600 mg
EU	EFSA Novel Food Approved	500 mg

3. Market Trends

• Sports Nutrition: 18% annual growth (35% market share in 2023).

• Cardiovascular Drugs: 12% CAGR (projected $420M by 2030).

8. References

• Zhou, X., et al. (2010). AMP-Na₂ improves coronary flow in ischemic heart disease. J. Cardiovasc. Pharmacol.

• Chen, L., et al. (2019). Neuroprotection by AMP-Na₂ in Alzheimer’s models. Neuropharmacology.

• Zhang, R., et al. (2021). Anti-fatigue effects of AMP-Na₂ in athletes. Sports Med.

AMP-Na₂ Specification

If you're interested in AMP-Na₂ into your supplement formulations, please reach out to JX Nutritional Chemical Co., Limited team. We will reply you as soon as possible.

Urolithin A

Back

Adenosine Triphosphate Disodium Salt (ATP-Na₂)

Get In Touch With Us